 Altimmune Inc NASDAQ: ALT revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges. The Phase 12 trial for T-COVID, single-dose intranasal therapeutic for early COVID-19, completed dosing in two of the three planned dose cohorts but could not fill the third cohort with patients over the age of 65 or with increased risk due to pre-existing comorbidities. 